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Background: Familial hypercholesterolemia can be efficiently treated with
combined lipid-lowering drugs. Lipid-lowering drugs are usually withdrawn
for pregnancy and breastfeeding, ideally preconception, followed by lipid aphe-
resis, however, careful plans can be precipitated due to unexpected pregnancy.
Case: A 28-year old woman with familial hypercholesterolemia due to heterozygous
LDLR mutations had an LDL-cholesterol level at 14.6 mmol/L and Lp(a) at
1150 mg/L. She required a three-vessel coronary artery bypass graft, drug-eluting
stents, rosuvastatin, ezetimibe, and alirocumab at maximal dosage. Contraception
was advised during the following 12 months, with a planned drug withdrawal to
bridge with lipid apheresis, such as the direct adsorption of lipoproteins (DALI).
However, an unplanned pregnancy required an abrupt stop of all oral medications at
six gestational weeks, except for aspirin. Lipid apheresis controlled LDL-cholesterol
in the range of 4.9–7.9 mmol/L (before DALI session) to 1.2–3.2 mmol/L (after DALI
session). Later, the regular pregnancy ultrasounds highlighted an isolated agenesis of
the corpus callosum later confirmed by magnetic resonance imaging.
Conclusions: A causal link between the early pregnancy exposure to PCSK9
inhibitors (or statins and ezetimibe taken concomitantly) and the observed
complete agenesis of the corpus callosum seems unlikely in this case. Guide-
lines do not specifically recommend preconception measures to lower fetal
and/or maternal risks of patients with severe FH considering pregnancy. We
argue that lipid apheresis and other measures should be discussed with women
with FH and maternity project on an individual basis, until phar-
macoepidemiology studies assessing the safety of PCSK9 inhibitors in preg-
nancy are available.
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1 | INTRODUCTION
Familial hypercholesterolemia (FH) is a autosomal domi-
nant disease causing elevated low-density lipoprotein
cholesterol levels (LDLc) and cardiovascular diseases at
early age (Mach et al., 2020). Clinical guidelines recom-
mend combined treatment to lower LDLc with intensive
lifestyle programs, high-intensity statin, and ezetimibe.
When the target LDLc level cannot be achieved, mono-
clonal antibodies targeting proprotein convertase subtili-
sin/kexin type 9 (PCSK9) are the next therapeutic option
(Mach et al., 2020; Thompson et al., 2017). This novel
drug class can be used in all adults, including young
women of childbearing age, although reproductive safety
data are missing. In rare situations, extracorporeal clear-
ance of lipoproteins with lipid apheresis is required to
control LDLc in FH, especially when the aforementioned
therapies are not tolerated or contraindicated (France
et al., 2016; Mach et al., 2020; Watts et al., 2015). Here,
we report the clinical case of a woman with FH who
became pregnant while on statin, ezetimibe, and a
PCSK9 inhibitor.
2 | CASE REPORT
At medical check-up, a 28-year-old Caucasian woman
reported exertion dyspnea. She was otherwise healthy
and sedentary, but reported second-hand smoking at
home. Her father had had a hemiparetic stroke at 50 and
a fatal heart infarct at 52 years old. Her mother's total
cholesterol varied between 6 and 7 mmol/L. The patient's
blood pressure was 117/67 mmHg, BMI 23.8 kg/m2 and
the arterial pulses were symmetrical. We found no arcus
cornealis, no xanthelasma, no Achilles tendon xan-
thomata, but probable tendinous xanthomata on both
hands.
Presumptive FH was diagnosed based on her LDLc
level at 14.6 mmol/L (Table 1). After a clinically negative
but electrically positive ergometry, a coronary angiogra-
phy revealed a three-vessel coronary heart disease and
she underwent a coronary artery bypass graft (CABG).
The medical treatment included acetylsalicylic acid
100 mg, clopidogrel 75 mg, rosuvastatin 20 mg, ezetimibe
10 mg once daily, and alirocumab subcutaneously every
2 weeks, and lowered LDLc to 3.8 mmol/L.
FH was confirmed with two distinct heterozygous
missense LDLR mutations: c.81C > G/p.Cys27Trp (15–
30% residual activity) and c.1646G > A/p.Gly549Asp
(residual activity <2%) both classified as likely patho-
genic (Hobbs, Brown, & Goldstein, 1992). No APOB or
PCSK9 mutation was found. Parents and siblings could
not be sequenced, and chromosomal analyses were not
performed. The complete status of LDLR mutations could
not be formally confirmed, but based on the clinical pre-
sentation of very high LDLc and early atherosclerosis, we
presume a compound heterozygous mutation with both
missense mutations compromising LDLR activity.
As the patient was considering maternity, contracep-
tives were advised for at least 12 months after CABG.
Preconception drug withdrawal was planned with a
bridge to lipid apheresis (France et al., 2016; Ogura
et al., 2016; Watts et al., 2015), such as the Direct Adsorp-
tion of Lipoproteins (DALI).
TABLE 1 Evolution of the lipid profile before, during, and after pregnancy






week 7 Gestational week 10 At 3 months







Total cholesterol, mmol/L 17.0 5.7 5.3 9.6 5.7 6.3
HDL-cholesterol, mmol/L 2.6 1.3 1.3 1.3 1.1 1.1
LDL-cholesterol, mmol/L 14.6 3.8 3.7 7.9 4.3 4.7
Triglycerides, mmol/L 1.2 1.3 0.6 0.9 0.6 1.0
Apolipoprotein A1, g/L 1.13 1.34 – 1.26 1.08 –
Apolipoprotein B, g/L 3.80 1.12 – 2.15 1.28 –
Lipoprotein (a), mg/L – 1,150 – 918 483 –
Abbreviations: DALI, direct adsorption of lipoproteins technique of lipid apheresis; FH, familial hypercholesterolemia; HDL, high-density lipoproteins; LDL,
low-density lipoproteins.
aThe three drugs consisted of rosuvastatin 20 mg once daily, ezetimibe 10 mg once daily, and alirocumab 150 mg subcutaneously every 2 weeks.
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However, an unplanned pregnancy occurred after
9 months. Except for acetylsalicylic acid, all oral medica-
tions were stopped 7 weeks after the last menstrual
period and pregnancy multivitamins were introduced.
The last dose of alirocumab was self-injected 16 days
after the last menstrual period. To control the rising
LDLc throughout pregnancy, DALI sessions were started
and the interval was adapted between 4 and 10 days
(Figure 1) according to pretreatment LDLc and the esti-
mated mean LDLc with the Kroon formula (Kroon
et al., 2000). DALI was performed through a tunneled
cuffed internal jugular catheter with the Art Universal
device (Fresenius Medical Care) using two 500-ml adsorbers
in series. The circuit was primed with heparin, of which
1,500 IU were delivered to the patient, and clotting was
prevented by regional citrate anticoagulation (ACD-A solu-
tion, 275 ml per session). Calcium glubionate was infused
continuously to prevent hypocalcemia. Hypovolemia related
to the priming of lines and columns (total 580 ml) was
prevented by NaCl 0.9% infusion. Each DALI session lasted
an average of 145 min, processed 7.4 L of blood with a max-
imal blood pump flow of 60 ml/min.
2.1 | Complete agenesis of the corpus
callosum detected in utero
First trimester ultrasound did not show signs of aneu-
ploidy. The anatomy ultrasound at 20 gestational weeks
suspected an isolated complete agenesis of the corpus cal-
losum, later confirmed by fetal magnetic resonance imag-
ing at 22 gestational weeks (Figure 2). The comparative
genomics hybridization array (Agilent oligoNT array
CGH 180 K) was normal.
FIGURE 1 Evolution of the lipid profile during lipid apheresis. Before pregnancy (on the left of the y-axis), the total and LDL
cholesterol (gray and orange circles, respectively) were reduced with the combined treatment of rosuvastatin 20 mg once daily, ezetimibe
10 mg once daily, and alirocumab 150 mg subcutaneously every 2 weeks. Last alirocumab injection was done 16 days after the last
menstrual period and ezetimibe and rosuvastatin were stopped at seven gestational weeks after the pregnancy was confirmed (on the right of
the y-axis). A complete agenesis of the corpus callosum was confirmed with a fetal MRI at 22 gestational weeks. During pregnancy and in
the postpartum period, lipid apheresis sessions were performed at regular intervals to control total and LDL cholesterol (gray and orange).
The interval between each session was adapted throughout pregnancy (every 7 days, unless stated otherwise in the figure) according to
pretreatment LDLc and the estimated mean LDLc with the Kroon formula (Kroon, van't Hof, Demacker, & Stalenhoef, 2000)
FIGURE 2 Fetal MRI (left
panel, frontal; right panel,
sagittal) realized at
22 gestational weeks
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Cesarean delivery was performed at 40 gestational
weeks, due to fetal bradycardia at 7 cm dilation after
spontaneous labor. The male newborn had an Apgar
score of 10–10–10, an arterial pH at 7.25, and venous pH
at 7.31. The birth length was 49 cm (25th percentile),
weight 3,220 g (50th percentile) and head circumference
35 cm (50th percentile), with normal clinical examina-
tion at birth.
The infant showed normal developmental milestones
and neurological examination until the last clinical visit
at 9 months of age. His LDLc was elevated at 3.5 and
5.0 mmol/L at 2 and 7 months, respectively. We could
not find any exposure factors, in particular no toxic or
alcohol before or during pregnancy.
3 | DISCUSSION
To our knowledge, this is the first report of exposure to
PCSK9 inhibitors in early pregnancy. A causal link
between the early pregnancy exposure to this drug
(or statins and ezetimibe taken concomitantly) and the
complete agenesis of the corpus callosum cannot be
assessed based on a single case.
The accountability of the drugs in congenital midline
defect can be considered unlikely for several reasons.
First, the sensitive period for the corpus callosum devel-
opment is probably not in the first 10 weeks of preg-
nancy. Based on the last use of the three lipid-lowering
drugs and their half-lives, the exposure period did not
extend beyond 10 weeks, even when accounting for the
alirocumab half-life of 12 days (i.e., stopped at 16 days
after the last menstrual period +4 half-lives expected to
reach a 94% clearance leading to 9 weeks). Second,
monoclonal antibodies are not considered to cross the
placenta significantly before the second trimester (Pham-
Huy et al., 2019). No specific data are available on mono-
clonal antibodies targeting PCSK9, such as alirocumab,
but its placental transfer is not expected to differ dramati-
cally from other monoclonal antibodies. Finally, recent
data with a strong level of evidence on statins safety in preg-
nancy did not confirm the previously observed association
between statins and teratogenic risks (Bateman et al., 2015;
Botha, Pilcher, Wolmarans, Blom, & Raal, 2018).
Clinical guidelines do not recommend specific pre-
conception measures to lower fetal and/or maternal risks
of patients with severe FH considering pregnancy. Our
patient reported good tolerance to lipid apheresis
throughout pregnancy. We argue that lipid apheresis and
other relevant measures should be discussed before preg-
nancy with women with FH on an individual basis, until
large pharmacoepidemiology studies assessing the safety
of PCSK9 inhibitors in pregnancy are available.
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